1

AbCheck s.r.o.An Antibody Technology and Discovery Company

Company Presentation

2

Profile

2

AbCheck is an antibody technology and discovery company We are specialising in discovery and generation of fully human antibodies Our services range from antibody discovery to lead optimization We have a track record of isolating more than 25 different antibodiesThe antibodies are derived from 3 diverse human librariesUsing 3 different libraries significantly increases the likelihood of successWe are dedicated to finding the antibody that best meets the customer´s needs AbCheck is located in Plzen, Czech Republic, combining attractive cost structure with full freedom to operate and no commercial obligations to third parties

3

Management

Dr. Volker Lang (Managing Director)16 years experience in the biotechnology sector, spanning basic research, industryR&D, Business Development and Licensing, commercial operations and managementBackground as scientist and project manager combined with extensive experience inthe commercialization of biotechnology productsConsiderable CMC/Production experience in his previous positions as Chief Business Officer (Affimed Therapeutics AG) and Vice President Corporate Development (Scil Technology GmbH)

Dr. Vera Molkenthin (Chief Scientist and Head of Discovery)Many years experience in the selection of antibodies using phage displayPhD from the Faculty of Biology in Mainz with main focus on construction of a phagedisplay library and the selection of stabilizing mutationsHead of Screening at Affimed with responsibility for the management of the screeninggroup, with special emphasis on generation of highly diverse antibody libraries, anddesign and execution of the most appropriate selection procedure for a particulartarget

4

Superior Technology

AbCheck is using three distinct fully human librariesNatural library derived from immune system’s antibody gene repertoireFully synthetic librarySemi-synthetic library combining aspects of both naïve and synthetic antibody libraries

AdvantagesHigher probability of isolating very specific human antibodies against any target High diversity; approximately 1010 not only in sequence, but also in structural diversity

ValidationQuality of libraries validated by more than 10 pre-clinical programsOutstanding screening expertise proven by isolation of >25 different molecules including:

Several complex cell surface receptors as well as GPCRSubnanomolar affinitiesVery high specificity

5

Fully human libraryIn vivo created diversity of antibody sequences comprising sequential as well as structural diversityNew combinations of VH and VL chains from multiple healthy donorsNo bias due to amplification of the VH chains by IgM specific primingSpecial assembly technology guarantees > 70% functional clones

Natural Antibody Library

Reliable and rapid selection of highly specific and high affinity antibodies on recombinant proteins or cells

6

Synthetic Library

Synthetic libraryGenerated by introducing randomized sequences in the antibody binding site of selected frameworksEnsuring reliable folding and high expression yieldsDiversity generated in vitro thereby Avoiding counter selection against anti-self antibodies

Semi-synthetic libraryCombining the advantages of the natural and synthetic libraryDiversity and reliable folding and high expressionIncreasing the diversity of binding molecules even further

7

Semi-Synthetic Library

8

Track record in isolating AntibodiesProven track record of more than 25 different antibodies isolated including:

High affinity bindersExtreme specificitiesTargets including complex surface receptors as well as GPCR

Sophisticated screening approaches developedAdapted to requirements of different targetsDifferential screeningScreening on the surface of eukaryotic cells, etc.

Strong Experience in Lead OptimizationSelection of most suitable antibody for custom’s need from usually more than five different candidatesAffinity maturation by light chain shuffling and randomization of contact residues

9

Affinity and affinity maturation

Examples of scFv affinities(measured by surface plasmon resonance, SPR)

Affinities in recent screenings within the low nanomolar RegionAffinities increasing with library optimizationMonovalent BindingTransfer into bivalent IgG usually increases binding strength by orders of magnitude

Affinity maturationIf required several means of affinity maturation can be appliedAffinities can be increased by several orders of magnitude

10

Specificity and FunctionalitySpecificity

Antibody specifically binding the A isoform of the FcgRIII receptor CD16ANot binding to the B isoform despite 96% homologyTargeting exclusively the activated form of the platelet receptor GPIIb/IIIa

FunctionalityBinding to eukaryotic tumor or other cells expressing targets on their surface

ExamplesAnti GPIIb/IIIa antibody: inhibiting binding of fibrinogen to activated thrombocytesAnti IL13R antibody: Interruption of the IL13 signalling cascade

The diagram illustrates the percentage of cell-binding antibodies among all antibodies isolated in a protein-based panning

process. If the target is a cell surface protein AbCheck guarantees binding of the isolated antibodies to target cells by this technique in most cases. Alternatively, panning on the cell

surface is used.

The diagram illustrates the percentage of cell-binding antibodies among all antibodies isolated in a protein-based panning

process. If the target is a cell surface protein AbCheck guarantees binding of the isolated antibodies to target cells by this technique in most cases. Alternatively, panning on the cell

surface is used.

11

Our Discovery Capabilities

Target Expression

Cloning of target proteinsProduction in bacterial or eukaryotic expression systems

Screening

Screening for binders to the recombinant antigenDifferential screening to exclude certain specificitesScreening on the surface of eukaryotic cellsTests for binding to recombinant antigens (ELISA)Tests for cell binding (FACS)Affinity rankingThe entire sequencing processThe cloning of sub-libraries for affinity maturation

Characterization

Recloning in the IgG formatProduction in eukaryotic cellsPurificationSpecificityAffinityIn vitro functionality

12

The AbCheck Value Chain

Superior Antibody Seqence

Human Sequence

High Affinity

Specificity highly adapted to functional requirements of targets

13

Business StrategyEstablishing partnerships with renowned biotechnology and pharmaceutical companiesGenerating revenues by:

R&D fundingUpfront Fees Milestones paymentsRoyalties on end products

AbCheck’s potential clients include:Large Pharma/Biotech Midsized companies Product orientated companies based on novel platform technologies Small Biotech companies with proprietary targets

14

Partner Benefits

Highly productive and validated technologySenior team with a proven track record of over ten years in discovery and research of therapeutic antibodiesStrong IP positionNo royalty obligations to third partiesFlexible, tailor-made deal structure

High grade of technology validation combined with attractive cost structures

15

Typical Deal Values

16

Why partner with us?

AbCheck uses three distinctly different proprietary human antibody libraries containing about 1010 antibodiesThe use of three different libraries offers a significantly higher chance to identify the antibody that best meets the customer’s needsProven track record of isolating more than 25 different fully human antibodiesExperienced management team with a proven track record and over 10 years experience in isolating antibodiesAbCheck combines a high grade of technology validation with attractive cost structure, no royalties and no commercial obligations to third parties

17

Contact

Volker Lang, PhD(Managing Director)

Phone: +420 378 05 1500 V.Lang@AbCheck.eu

AbCheck s.r.o.

Vedeckotechnicky park Plzen

Teslova 3

CZ-301 00 Plzen

www.AbCheck.eu